PhRMA sent a letter to President Biden on March 5, 2021, signed by 31 PhRMA board members, welcoming his Administration’s focus on the pandemic, underscoring the unprecedented collaboration underway and warning that undermining intellectual property would impede our collective response to COVID-19 and emerging variants.